Plerixafor and Filgrastim XM02 (Tevagastrim ®) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation

Giovanna Andreola, Aleksandra Babic, Cristina Rabascio, Mara Negri, Giovanni Martinelli, Daniele Laszlo

Research output: Contribution to journalArticle


Plerixafor, a CXCR4 antagonist, has shown to be effective in increasing the number of circulating stem cells, even in patients failing a previous mobilisation attempt. Recently a number of non-glycosylated recombinant human granulocyte-colony stimulating factor (G-CSF) has been clinically approved for the same indications as the originator G-CSF for comparable safety and efficacy and their reduced cost. In an attempt to provide a less toxic strategy, 14 patients affected by haematological malignancies (non-Hodgkin's lymphoma=4, Hodgkin's disease=2 and multiple myeloma=8), received the combination of biosimilar filgrastim and plerixafor as a first line mobilising strategy. The median number of circulating CD34+ cells on day 4 was 16 (3-42); Plerixafor was administered to all, but one patient who had already 42 CD34+ cells per μL on day 4. On day 5, after plerixafor administration, the median number of circulating CD34+ cells had raised to 60 per μL (14-138). All the patients underwent leukapheresis and were able to collect a number of CD34+ cells ≥2.0×10 6/kg in a median number of procedures of one. Although preliminary, these data show the combination of biosimilar filgrastim and plerixafor is effective and provides a non-toxic approach to mobilise stem cells.

Original languageEnglish
Pages (from-to)154-158
Number of pages5
JournalEuropean Journal of Haematology
Issue number2
Publication statusPublished - Feb 2012



  • Biosimilar granulocyte colony-stimulating factor
  • CD34+ cells
  • Plerixafor
  • Stem cell mobilisation

ASJC Scopus subject areas

  • Hematology

Cite this